Drug
TD 9855
TD 9855: highest development phase Phase 2, developed by Theravance Biopharma. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Theravance Biopharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| TD-9855 NCT02705755 | Phase 2 | Neurogenic Orthostatic Hypotension |
| TD-9855 NCT01924143 | Phase 1 | ADHD |
Latest
Follow TD 9855 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.